Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.75 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.75 |
| ▸ | HCK | P08631 | 9/20 | 0.64 |
| ▸ | TNF | P01375 | 2/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.63 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 3/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296301 | 0.91 | MAPK14 (0.73) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL4085600 | 0.88 | MAPK14 (0.68) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL18305786 | 0.86 | MAPK14 (0.70) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL4092660 | 0.86 | MAPK14 (0.69) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL295580 | 0.85 | MAPK14 (0.68) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL29593405 | 0.85 | MAPK14 (0.68) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL6806388 | 0.83 | MAPK12 (0.53) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL295750 | 0.82 | MAPK14 (0.64) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL29594500 | 0.82 | MAPK14 (0.64) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL6298539 | 0.81 | MAPK14 (0.76) | MAPK14MAPK12HCKTNFMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| EP-1147104-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6525046-B1 | Inhibits inflammatory cytokines such as interleukin-1 and tumor necrosis factor; 1-(5-(2-hydroxy-1,1-dimethyl-ethyl) -2-p-tolyl-2H-pyrazol-3-yl)-3- (4-(2- morpholin-4-yl-ethoxy)-naphthalen-1-yl)-urea | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-6506748-B2 | For therapy of diseases or pathological conditions involving inflammation such as chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6492529-B1 | PHARMACEUTIC COMPOSITIONS FOR TREATING DISEASES OR PATHOLOGICAL CONDITIONS INVOLVING INFLAMMATION SUCH AS CHRONIC INFLAMMATORY DISEASES. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020065285-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | HICKEY EUGENE R (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020058678-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | CIRILLO PIER F (US) | 2002-05-16 | — | — | US | disclosed |
| US-6372773-B1 | TREATMENT OF INFLAMMATION, ARTHRITIS WITH UREA OR THIOUREA HETEROCYCLES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-6333325-B1 | ADMINISTERING PYRAZOLE DERIVATIVE OF UREA OR THIOUREA FOR THERAPY OF CYTOKINE MEDIATED DISEASE SUCH AS ACTUATE AND CHRONIC PAIN, CONTACT DERMATITIS, ATHEROSCLEROSIS, GLOMERULONEPHRITIS, REPERFUSION INJURY, BONE RESORPTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-25 | — | — | US | disclosed |
| US-6329415-B1 | INHIBIT RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-6319921-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, CROHN'S DISEASE ULCERATIVE COLITIS, PSORIASIS, GRAFT VERSUS HOST DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS AND DIABETES | BOERHINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK12 436/4885HCK 4299/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | MAPK14 193/4885MAPK12 528/4885HCK 4372/4885 |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 196/4885MAPK12 446/4885HCK 4494/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK12 436/4885HCK 4299/4885 |
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | IL2, IFNG, IL1A | MAPK14 3143/4885MAPK12 3606/4885HCK 3195/4885 |
| US-20020065285-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | FPR1, AHR, FPR2 | MAPK14 3755/4885MAPK12 3590/4885HCK 4096/4885 |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK12 436/4885HCK 4299/4885 |
| US-20020058678-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | FPR1, AHR, FPR2 | MAPK14 3755/4885MAPK12 3590/4885HCK 4096/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK12 436/4885HCK 4299/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK12 436/4885HCK 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.